Facilitation of μ-Opioid Receptor Activity by Preventing δ-Opioid Receptor-Mediated Codegradation  by He, Shao-Qiu et al.
Neuron
ArticleFacilitation of m-Opioid Receptor Activity
by Preventing d-Opioid Receptor-
Mediated Codegradation
Shao-Qiu He,1,3 Zhen-Ning Zhang,2,3 Ji-Song Guan,1,3 Hong-Rui Liu,2 Bo Zhao,1 Hai-Bo Wang,1,2 Qian Li,2 Hong Yang,1
Jie Luo,2 Zi-Yan Li,2 Qiong Wang,2 Ying-Jin Lu,1 Lan Bao,2,* and Xu Zhang1,*
1Institute of Neuroscience and State Key Laboratory of Neuroscience
2Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology
Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, P.R. China
3These authors contributed equally to this work
*Correspondence: baolan@sibs.ac.cn (L.B.), xu.zhang@ion.ac.cn (X.Z.)
DOI 10.1016/j.neuron.2010.12.001SUMMARY
d-opioid receptors (DORs) form heteromers with
m-opioid receptors (MORs) and negatively regulate
MOR-mediated spinal analgesia. However, the
underlying mechanism remains largely unclear. The
present study shows that the activity of MORs can
be enhanced by preventing MORs from DOR-medi-
ated codegradation. Treatment with DOR-specific
agonists led to endocytosis of both DORs and
MORs. These receptors were further processed for
ubiquitination and lysosomal degradation, resulting
in a reduction of surface MORs. Such effects were
attenuated by treatment with an interfering peptide
containing the first transmembrane domain of
MOR (MORTM1), which interactedwith DORs and dis-
rupted the MOR/DOR interaction. Furthermore, the
systemically applied fusion protein consisting of
MORTM1 and TAT at the C terminus could disrupt
the MOR/DOR interaction in the mouse spinal cord,
enhance the morphine analgesia, and reduce the
antinociceptive tolerance to morphine. Thus, disso-
ciation of MORs from DORs in the cell membrane
is a potential strategy to improve opioid analgesic
therapies.
INTRODUCTION
G protein-coupled receptors (GPCRs) are known to form hetero-
mers that may modulate the physiological and pharmacological
functions of GPCRs (Gurevich and Gurevich, 2008). Functional
association between m- and d-opioid receptors (MORs and
DORs), two members of the GPCR superfamily, was first sug-
gested by pharmacological studies showing that MOR activity
could be modulated by DOR ligands (Lee et al., 1980; Schiller
et al., 1999). The heteromers of MORs and DORs were identified
in both cotransfected cells and membranes prepared from the
spinal cord (Daniels et al., 2005; Fan et al., 2005; Gomes et al.,120 Neuron 69, 120–131, January 13, 2011 ª2011 Elsevier Inc.2004; Jordan and Devi, 1999). In the lamina I–II of spinal cord,
the agonist-binding sites and immunoreactivity of DORs are
located in the afferent fibers of small dorsal root ganglion
(DRG) neurons, and these presynaptic DORs mediate the inhib-
itory effects of opioid peptides released from spinal dorsal horn
neurons (Besse et al., 1992; Cesselin et al., 1989; Mennicken
et al., 2003; Minami et al., 1995; Zhang et al., 1998a). MORs,
which are a major target of opioid analgesics such as morphine,
are also expressed in small DRG neurons and might be coex-
pressedwith DORs (Ji et al., 1995; Rau et al., 2005). Interestingly,
MOR-mediated analgesia can be enhanced by pharmacologi-
cally blocking DORs, preventing DOR phosphorylation, and
genetically deleting either the exon 2 of DOR1 gene (Oprd1) or
the preproenkephalin gene (Chefer and Shippenberg, 2009;
Gomes et al., 2004; Nitsche et al., 2002; Schiller et al., 1999;
Standifer et al., 1994; Xie et al., 2009; Zhu et al., 1999). Therefore,
DORs could negatively regulate MOR activity in the spinal cord
and may be involved in m-opioid antinociceptive tolerance.
The cellular basis for the opioid receptor interaction was ques-
tioned because a DOR1 protein fused with the enhanced green
fluorescence protein (DOR1-EGFP) could not be detected
in MOR-containing small DRG neurons (Scherrer et al., 2009).
Recently, the coexistence of MORs and DORs in small DRG
neurons has been shown using multiple approaches, such
as single-cell PCR, in situ hybridization combinedwith immunos-
taining and electrophysiological recording (Wang et al., 2010).
Additionally, Gupta et al. (2010) detected the receptor
heteromers in DRG neurons using antibodies that recognize
MOR/DOR heteromers. Given that the receptor coexistence is
a cellular basis for the modulation of opioid analgesia, the mech-
anisms underlying the DOR-mediated modulation of the MOR
activity in the pain pathway remain largely unclear.
Cell biological studies have shown that GPCRs activated by
selective agonists are often internalized and processed in either
the recycling pathway for resensitization or the degradation
pathway that leads to receptor downregulation (Trapaidze
et al., 2000; Tsao and von Zastrow, 2000). It has been proposed
that heteromerized GPCRs may traffic via a postinternalization
pathway that is different to the one used when they are ex-
pressed alone. Therefore, receptor heteromerization may serve
as a regulatory mechanism for controlling receptor availability
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It has been shown that internalized MORs and DORs are differ-
entially processed in postendocytotic pathways. Internalized
MORs are mainly recycled to the cell surface and re-sensitized
after treatment with a MOR-specific agonist, [D-Ala2, N-Me-
Phe4, Gly-ol5]-enkephalin (DAMGO) (Arden et al., 1995; Finn
and Whistler, 2001; Law et al., 2000). In contrast, internalized
DORsweremainly found to be located in the lysosomal compart-
ments for degradation after treatment with DOR agonists (Hislop
et al., 2009; Trapaidze et al., 1996; Tsao and von Zastrow, 2000).
Agonist-induced receptor phosphorylation and ubiquitination
(Hicke, 1997; Katzmann et al., 2002) were reported to be
involved in the endocytosis and downregulation of opioid recep-
tors (Finn andWhistler, 2001; Hislop et al., 2009). MOR/DOR het-
eromers were also reported to recruit b-arrestin, which modified
the dynamics of opioid-mediated extracellular signal-regulated
kinase (ERK) activation (Rozenfeld and Devi, 2007). However,
whether postendocytotic trafficking of MORs can be modulated
by DORs remains to be examined. Furthermore, if DORs and
MORs were colocalized in sensory afferent fibers, it would be
interesting to explore the physical interaction and functional
correlation between these two types of opioid receptors in vivo.
The aim of the present study was to investigate the postendo-
cytotic process of the MOR/DOR complex after agonist
stimulation and its correlation with the DOR-mediated negative
regulation of MOR-mediated spinal analgesia. We found that
the activation of DORs in the MOR/DOR complex could target
MORs into the postendocytotic degradation pathway, resulting
in MOR desensitization. Furthermore, morphine analgesia could
be facilitated by disrupting the MOR/DOR interaction with an
interfering peptide that corresponds to the first transmembrane
domain (TM1) of MOR fused with the TAT peptide, which is the
cell membrane transduction domain of the human immunodefi-
ciency virus and used as a cell-penetrating vector to deliver small
cargos or large molecules (Schwarze et al., 1999). Therefore,
physical disassociation of MORs from DORs could be a strategy
to enhance MOR-mediated analgesia.
RESULTS
Cointernalization of MORs and DORs
following Agonist Treatment
To assess whether MOR trafficking could be modulated by acti-
vation of DORs, we examined the distribution and translocation
of MORs and DORs in human embryonic kidney 293 (HEK293)
cells that were cotransfected with plasmids expressing MOR
with an N-terminal hemagglutinin (HA) tag (HA-MOR) and DOR
with an N-terminal Myc tag (Myc-DOR). Because HA and Myc
were tagged at the N termini of MOR and DOR, respectively,
and exposed to the extracellular space following insertion
of the receptors into the plasma membrane, HA-MOR and
Myc-DOR on the cell surface of living cells could be prelabeled
using rabbit anti-HA and mouse anti-Myc antibodies. Under
control conditions, the prelabeled DORs and MORs
were mainly present on the surface of the double-transfected
HEK293 cells (Figure 1A). Interestingly, after a 30 min treatment
with the selective DOR agonists deltorphin (Delt) I, Delt II, or
(+)-4-[(aR)-a-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-me-thoxybenzyl]-N,N-diethylbenzamide (SNC80) (1 mM), the prela-
beled DORs and MORs were cointernalized and colocalized
in the same vesicular structures (Figure 1A). When DAMGO
(1 mM), a selective MOR agonist, was applied for 30 min, the
cointernalization of prelabeled MORs and DORs was also
observed in the double-transfected HEK293 cells (Figure 1A).
The reaction induced by Delt I or DAMGO could be abolished
using the DOR antagonist naltrindole (NTI) or the MOR
antagonists naloxone and D-Phe-Cys-Tyr-D-Trp-Om-Thr-Pen-
Thr-NH2 (CTOP) (Figure 1A), indicating that the receptor coin-
ternalization is induced in a receptor-specific manner.
DOR-mediated cointernalization of DORs and MORs was
further confirmed by direct measurement of the amount of
receptors present on the cell surface using immunoblotting.
After agonist treatment, the proteins that remained on the
surface of HEK293 cells cotransfected with the plasmids
expressing Myc-DOR and MOR fused with a Flag tag at the
C terminus (MOR-Flag) were biotinylated and precipitated with
immobilized streptavidin. Treatment with Delt I or SNC80 led to
a marked reduction of both MORs and DORs on the cell surface
(Figure 1B and see Figure S1A available online). These results
indicate that a receptor-selective agonist can induce the coin-
ternalization of both types of opioid receptors.
Receptor phosphorylation is involved in d-opioid peptide-
induced DOR internalization and DAMGO-induced MOR
internalization (Pak et al., 1999; Whistler et al., 2001). We
observed that receptor-specific phosphorylation was involved
in the agonist-induced cointernalization of MORs and DORs.
In HEK293 cells coexpressing Myc-DOR and MOR-Flag, immu-
noblotting showed that treatment with Delt I (1 mM) or SNC80
(5 mM) for 30 min selectively enhanced DOR phosphorylation,
while DAMGO (1 mM) selectively increased MOR phosphoryla-
tion (Figures 1C and S1B). Thus, receptor-selective agonists
specifically induce phosphorylation of the corresponding type
of opioid receptor. This result also suggests that the DOR
agonist-induced cointernalization of MORs and DORs is not
due to a cross-reaction of the agonist or to a transphosphoryla-
tion of MORs by activation of DORs.
The role of the phosphorylation and internalization of DORs
in the cointernalization of MORs was further evaluated by
coexpressing MOR-Flag with a Myc-tagged, phosphorylation-
deficient DOR mutant [Myc-DOR (M)] in which all serine and
threonine residues (T352, T353, T358, T361, and S363) in the
C terminus were mutated to alanine residues (Whistler et al.,
2001). In Myc-DOR (M) and MOR-expressing HEK293 cells,
neither surface Myc-DOR (M) nor surface MORs were internal-
ized following a Delt I or SNC80 (1 mM) treatment for 30 min
(Figures 1D and S1C). These results confirm that activated
DORs are required for cointernalization of MORs.
Targeting Surface MORs into the Degradation
Pathway by Activation of DORs
Next, we determined the postendocytotic fate of MORs cointer-
nalized with DORs. Using triple-immunofluorescence staining in
MOR- and DOR-expressing HEK293 cells, we observed that
a 90 min treatment with Delt I (1 mM), but not DAMGO (1 mM),
significantly increased the localization of MORs in lysosome-
like compartments that were labeled using a LysoTracker probeNeuron 69, 120–131, January 13, 2011 ª2011 Elsevier Inc. 121
Figure 1. Receptor-Specific Agonist
Induces Cointernalization of MORs and
DORs
(A) Plasmids expressing HA-MOR and Myc-DOR
were cotransfected into HEK293 cells. The HA-
MORs and Myc-DORs present on the cell surface
were labeled with antibodies against HA (in green)
or Myc (in red), respectively. In the control cells,
the prelabeled MORs and DORs were mainly
localized on the cell surface. After a 30 min treat-
ment with 1 mMSNC-80, Delt I, Delt II, or DAMGO,
the prelabeled MORs and DORs were internalized
and colocalized in vesicular structures (arrows).
The Delt I- and DAMGO-induced cointernalization
of DORs and MORs could be attenuated by 5 mM
NTI, naloxone (NLX), or CTOP, respectively.
The quantitative data show the ratio of the
staining for internalized MORs or DORs versus
the total surface immunostaining. Results are pre-
sented as mean ± SEM. ***p < 0.001 versus the
control; ###p < 0.001 versus indicated group. Scale
bar, 8 mm.
(B and C) The immunoblotting (IB) shows that in
HEK293 cells coexpressing Myc-DOR and MOR-
Flag, the levels of MORs and DORs on the cell
surface were reduced after a 30 min treatment
with 1 mM Delt I or SNC80 (B). A 30 min treatment
with 1 mM Delt I increases the phosphorylation
of DORs but does not affect that of MORs. Treat-
ment with 1 mM DAMGO only increased the
phosphorylation of MORs (C). Three independent
experiments showed similar results. Results are
presented as mean ± SEM. *p < 0.05 versus the
control.
(D) In HEK293 cells expressing MOR-Flag and the
phosphorylation-deficient DORmutant (Myc-DOR
(M)), the presence of receptors on the cell surface
was not reduced after Delt I or SNC80 treatment.
Results are presented as mean ± SEM.
See also Figure S1.
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showed that, in HEK293 cells coexpressing MOR-Flag and
Myc-DOR, a 30 min treatment with Delt I (1 mM) resulted in
a marked increase in the ubiquitination of both MORs and
DORs, whereas DAMGO (1 mM) did not noticeably change the
ubiquitination level of both MORs and DORs (Figure 2C).122 Neuron 69, 120–131, January 13, 2011 ª2011 Elsevier Inc.We further examined whether the coin-
ternalized MORs were degraded. The
surface proteins of transfected HEK293
cells were biotinylated before drug treat-
ment. DORs and MORs that remained
intact in the biotinylated proteins were
examined 90 min after treatment with
1 mM of Delt I or DAMGO. We observed
that the amount of biotinylated DORs
and MORs was significantly reduced
following the Delt I treatment, but no
significant changes were observed
following the DAMGO treatment (Figures
2D and 2E).DOR agonist-induced receptor degradation is known to
be sensitive to inhibitors of lysosomal proteolysis (Tsao and
von Zastrow, 2000) and MG132 (Tanowitz and von Zastrow,
2002), a compound that inhibits a number of proteasome-asso-
ciated proteases and potently suppresses the effect of various
cysteine proteases and cathepsins. We did not observe any
Figure 2. Activation of DORs Targets
Surface MORs into Degradation Pathway
(A and B) The HA-MOR and Myc-DOR present on
the cell surface of cotransfected HEK293 cells
were prelabeled with antibodies against HA (in
green) or Myc (in blue), and the lysosome-like
compartments were labeled using LysoTracker
(in red). After a 90 min treatment with 1 mM Delt I,
the internalized DORs and MORs were mainly
colocalized in the LysoTracker-labeled compart-
ments (arrowheads). After a 90 min treatment
with 1 mM DAMGO, the most vesicular structures
containing the internalized DORs and MORs
were not labeled by LysoTracker (arrows) (A).
The quantitative data show the percentage
of MOR-positive vesicular structures labeled
by LysoTracker (B). Results are presented as
mean ± SEM. **p < 0.01, n = 41. Scale bar, 8 mm.
(C) The immunoprecipitation (IP) experiment
showed that ubiquitination of MORs and DORs in
HEK293 cells cotransfected with plasmids ex-
pressing MOR-Flag and Myc-DOR was enhanced
by a 30 min treatment with 1 mMDelt I. However, it
was not enhanced by 1 mM DAMGO.
(D and E) HEK293 cells expressing Myc-DOR and
MOR-Flag were surface-biotinylated before drug
treatment. Immunoblotting showed that the
amount of biotinylated DORs and MORs was
significantly reduced after 90 min treatment with
1 mM Delt I (D). Incubation of the cells with
100 mM leupeptin and 10 mM MG132 prevented
the Delt I-induced MOR/DOR degradation (D).
The quantitative data are plotted as a percentage
of the control (E). Results are presented as
mean ± SEM. **p < 0.01 and *p < 0.05 versus the
untreated cells (n = 3).
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pretreatment with a mixture of MG132 (10 mM) and leupeptin
(100 mM), a lysosomal protease inhibitor (Figures 2D and 2E).
Our results indicate that the cointernalized MORs and DORs
are targeted to lysosomes for degradation.
DOR-Mediated Downregulation of MORs in the Spinal
Cord and Attenuation of Morphine Analgesia
Both DOR binding sites and immunoreactivity were found to be
located in the afferent fibers of the lamina I–II of the spinal cord
(Besse et al., 1992; Mennicken et al., 2003; Zhang et al.,
1998a), which is enriched in MOR-containing afferent fibers
and local neurons (Zhang et al., 1998b). Using in situ double-
hybridization, we found that a large fraction of MOR-positive
small DRG neurons (79%, n = 643) expressed DOR1 (Figure 3A).
This result is consistent with our recent report (Wang et al., 2010).
DOR13–17 antiserum primarily recognizes DORs, as demon-Neuron 69, 120–131strated by the detection of Myc-DOR1
expressed in HEK293 cells (Figure S2A)
and the lack of DOR-immunoblots in
extracts of spinal cords from Oprd1
exon 1-deleted mice (Figure 3B). DOR1
could be detected in the spinal cord of
wild-type mice. Moreover, the DOR-im-munostaining pattern in the lamina I–II of the mouse spinal
cord could be abolished in Oprd1 exon 1-deleted mice and after
antiserum preabsorption with the immunogenic peptide (106 M)
(Figure 3C). Triple-immunofluorescence staining showed that
MOR/DOR-containing nerve terminals were frequently found in
the lamina I–II of the spinal cord and that many of them immuno-
stained for the calcitonin gene-related peptide (CGRP) (Fig-
ure 3D), which is a marker of peptidergic afferent fibers. In addi-
tion, a number of MOR-positive neurons and dendrites were
found in the spinal lamina II (Figure 3D). Thus, coexistence of
MORs and DORs in sensory afferent fibers provides a cellular
basis for the MOR/DOR interaction in the dorsal spinal cord.
Coimmunoprecipitation (coIP) showed that the MOR/DOR
interaction occurred in the spinal dorsal horn of mice and that
it was enhanced by intrathecal injection (i.t.) of Delt I (2 mg) for
15 min (215.2% ± 23.0% of control, p < 0.01, n = 5) (Figure 3E).
The specificity of the antibodies against DOR1–60 used for IP was, January 13, 2011 ª2011 Elsevier Inc. 123
Figure 3. Activation of DORs Reduces
Spinal MORs and Morphine Analgesia
(A) In situ double-hybridization with a digoxigenin-
labeled DOR1 probe and a fluorescein-labeled
MOR probe showed the coexistence of DOR and
MOR mRNAs in small DRG neurons of mice
(arrows). Thin arrows point to neurons containing
only MOR mRNA. Scale bar, 20 mM.
(B) Immunoblotting with DOR13–17 antiserum
showed that the DOR-immunoreactivity (arrows)
observed in the spinal cord extract from wild-
type mice was absent in samples from Oprd1
exon 1-deleted mice.
(C) Immunostaining with the antiserum (1:50,000)
showed DORs in the nerve fibers of the spinal
lamina I–II. This immunostaining pattern was abol-
ished in samples from Oprd1 exon 1-deleted mice
or when the antiserum was preabsorbed. Scale
bar, 50 mM.
(D) Triple-immunofluorescence staining showed
that MOR, DOR, and CGRP were colocalized in
afferent terminals (arrows) in lamina II of themouse
spinal cord. Arrowheads indicate a MOR-positive
neuron with a neurite (thin arrows). Scale bar,
8 mm.
(E) CoIP experiments with the anti-DOR11–60 anti-
body showed that the MOR/DOR interaction was
increased in the spinal dorsal horn after treatment
with 2 mg Delt I (i.t.) for 15 min. Three independent
experiments were performed with similar results.
(F) Immunoblotting with the DOR antiserum used
for coIP experiments showed that DOR immuno-
reactivity (arrows) observed in the spinal cord
extract from wild-type mice was absent in Oprd1
exon 1-deleted mice.
(G) Treatments with 5 mg Delt I or L-ENK (i.t., twice
at an interval of 15 min) increased the amount of
ubiquitylated MORs in the spinal dorsal horn.
Three independent experiments were performed
with similar results.
(H) After treatment with 1 mgDelt I (i.t., every 15min
for 1 hr), the intensity of MOR-immunostaining in
lamina I–II of the spinal cord was reduced. The
quantitative analysis was based on 3 sections/
mouse and 3 mice/group. Results are presented
as mean ± SEM. **p < 0.01 versus saline-treated
mice. Scale bar, 50 mm.
(I–K) The tail-immersion test at 52C showed that
morphine-induced analgesia was attenuated by
pretreatment with Delt I (i.t.) 30 and 45 min prior
to the morphine treatment (i.t.) (I). n = 10 at
15 min, n = 6 at 30 min, n = 8 at 45 min, and n = 6 at 60 min. Results are presented as mean ± SEM. ***p < 0.001 versus the saline-pretreated mice. Morphine
analgesia is dose-dependently reduced byDelt I applied 30min prior to themorphine treatment. This effect is blocked by cotreatment with NTI (i.t.) (J). Results are
presented as mean ± SEM. p < 0.01 for 0.25 mg, p < 0.001 for 0.5 mg, p < 0.01 for 1 mg, and p < 0.001 for 2 mg (ANOVA), n = 67 mice/group. A similar effect was
induced by pretreatment (i.t.) with L-ENK (p < 0.001, n = 7) or SNC80 (p < 0.001, n = 8) (J). Cotreatment with NTI (i.t.) increased the morphine (i.t.)-induced
analgesia (K). Results are presented as mean ± SEM. p < 0.001 (ANOVA), n = 11 and 8 mice for saline and NTI treatment, respectively. See also Table S1 (J)
and Table S2 (K).
See also Figure S2.
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cord of Oprd1 exon 1-deleted mice (Figures 3F and S2B).
A 45 min treatment with Delt I or SNC80 or leucine-enkephalin
(L-ENK) (5 mg, twice at an interval of 15 min, i.t.), an endogenous
DOR agonist expressed in dorsal horn neurons (Cesselin et al.,
1989), increased the ubiquitination of MORs (Figures 3G and124 Neuron 69, 120–131, January 13, 2011 ª2011 Elsevier Inc.S2C). Immunohistochemistry showed that the intensity of
MOR-immunostaining in the spinal lamina I–II was significantly
reduced in mice after a 1 hr treatment with Delt I (2 mg/15 min,
i.t.) (Figure 3H). These results suggest that the activation of
DORs leads to a downregulation of MORs in afferent fibers of
the spinal cord.
Figure 4. The TM1 Domain of MOR Medi-
ates MOR Interaction with DOR
(A) The diagram shows wild-type MORs, mutated
MORs (MOR(M)) with a substitution of MOR63–93
which contains the TM1 domain (MORTM1) with
MOR144–163 which contains the TM3 (MORTM3),
and MORTM1 fused with a-CGRP1–25 at the
N terminus and GFP at the C terminus.
(B and C) CoIP experiments showed that Myc-
DOR interacted with MOR-Flag in transfected
HEK293 cells; it only weakly interacted with MOR
(M)-Flag (B). The MOR/DOR interaction was mark-
edly reduced in the presence of MORTM1-GFP (B),
which could directly interact with Myc-DOR (C).
Each immunoblot represents three independent
experiments.
(D and E) In HEK293 cells coexpressing Myc-DOR
with MOR(M)-Flag, treatment with 1 mM Delt I for
30 min reduced the surface expression of DORs;
it did not affect the surface expression of MORs
(M). Treatment with 1 mM DAMGO induced the
internalization of MOR(M). Results are presented
as mean ± SEM. *p < 0.05, **p < 0.01 versus
untreated cells (n = 3).
(F) In triple-transfected HEK293 cells, the agoni-
st-induced cointernalization of HA-MOR and
Myc-DOR was attenuated by coexpressed
a-CGRP1–25-MORTM1-GFP. GFP-positive cells
were analyzed. Results are presented as mean ±
SEM. ***p < 0.001 versus the cells only expressing
HA-MOR andMyc-DOR (n = 39). Delt I (n = 42) and
DAMGO (n = 41)-treated cells were analyzed.
Scale bar, 4 mm.
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morphine analgesia. Using a tail-immersion test at 52C, we
found that morphine-induced spinal antinociception was mark-
edly attenuated when mice were pretreated with Delt I (1 mg,
i.t.) 30–45 min prior to the morphine treatment (1.5 mg, i.t.)
(Figure 3I). We also found that Delt I inhibited the morphine effect
in a dose-dependent manner when Delt I or SNC80 was applied
30 min prior to the morphine treatment (Figure 3J; Table S1).
A similar effect was induced by pretreatment with L-ENK (2 mg,
i.t.) (Figure 3J; Table S1). The Delt I-induced inhibition of
morphine antinociception was blocked by cotreatment with
NTI (Figure 3J; Table S1). Furthermore, NTI treatment (1 mg, i.t.)
facilitated morphine-induced spinal antinociception (Figure 3K;
Table S2). This result is consistent with previous findings (Gomes
et al., 2004). These data suggest that the DOR-mediated down-
regulation of MORs in the dorsal spinal cord leads to a reduction
in MOR-mediated analgesia.
First Transmembrane Domain of MOR Mediates
MOR Interaction with DOR
To fully evaluate the role of the MOR/DOR interaction in the
negative regulation of the MOR activity, we searched for theNeuron 69, 120–131domain of MOR that mediates its interac-
tion with DOR. Using the computational
analysis, Filizola and colleagues (2002)
predicted the TM1 domain of MORas the most likely binding interface with DOR. We constructed
amutatedMOR (MOR(M)) in whichMOR63–93 containing the pre-
dicted TM1 (MORTM1) was substituted byMOR144–163 containing
the predicted TM3 (MORTM3) (Figure 4A). CoIP experiments
showed that, while DOR interacted with MOR, it did not interact
with MOR(M) in cotransfected HEK293 cells (Figure 4B). We then
constructed a plasmid expressing a chimera protein that con-
tained TM1 with the signal peptide of a-CGRP fused at the
N terminus and a GFP fused at the C terminus (a-CGRP1–25-
MORTM1-GFP). The signal peptide of a-CGRP was used to sort
the fusion protein into the endoplasmic reticulum. It is then
removed by a signal peptidase, and the resulting GFP-tagged
MORTM1 is threaded through the membrane of the endoplasmic
reticulum. CoIP experiments showed that the MORTM1 peptide
interacted with coexpressed DORs in cotransfected HEK293
cells (Figure 4C), indicating that the TM1 domain of MOR medi-
ates the MOR interaction with DORs.
Using MOR(M) and a-CGRP1–25-MORTM1 as tools, we demon-
strated that a physical interactionwas essential for a cointernaliza-
tion of MORs and DORs. Treatment with Delt I (1 mM) did not lead
to a cointernalization of MOR(M) and DORs (Figures 4D and 4E).
This is not due to a problematic internalization of MOR(M), as, January 13, 2011 ª2011 Elsevier Inc. 125
Figure 5. Spinal MOR/DOR Interaction Can
Be Disrupted by MORTM1-TAT
(A) Cultured mouse DRG neurons were treated
with four types of fusion proteins containing the
TM1 or TM3 with the GST tag at the N terminus
and TAT at either the N or C terminus. Permeabi-
lized immunostaining with GST antibodies showed
that all fusion proteins weremainly localized on the
cell surface of small DRG neurons. Nonpermeabi-
lized immunostaining, which detects the GST tag
on the extracellular side of the plasma membrane,
showed that both MORTM1-TAT and MORTM3-
TAT, but not TAT-MORTM1 and TAT-MORTM3,
were inserted into the plasma membrane of small
DRG neurons in the same direction as that of TMs
in the native MOR. Scale bar, 8 mm.
(B) Mice treated with MORTM1-TAT (i.p., three
injections within 2.5 hr, 10 mg/kg/injection) were
subjected to pre-embedding immunogold-silver
labeling. Light microscopy analysis (upper panel)
showed MORTM1-TAT-labeling in the nerve termi-
nals in the dorsal horn of the lumbar spinal cord,
with a high intensity of immunostaining in the
lamina I–II. The boxed area shows the sample at
a high magnification. At the ultrastructural level
(lower panel), MORTM1-TAT-labeling was associ-
ated with the plasma membrane of the afferent
terminals of the glomerulus in the lamina II. Arrows
point to the postsynaptic zone. Scale bars, 100 mm
for light micrographs and 200 nm for electron
micrographs.
(C and D) CoIP experiments showed that the basal
MOR/DOR interaction in the mouse spinal cord
was reduced after a 2.5 hr pretreatment with
MORTM1-TAT (i.p., three injections, 10 mg/kg/
injection); the interactions between MORs and
a2A-AR or NK1-R were unaffected (C). The same
pretreatment also reduced theMOR ubiquitination
induced by treatment with 5 mg Delt I but did not
affect that of DORs (D). Three independent exper-
iments were performed. Results are presented as
mean ± SEM. **p < 0.01 versus control mice.
See also Figure S3.
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MOR(M) (Figures 4D and 4E). Consistently, a 30 min treatment
with DAMGO (1 mM) did not induce a cointernalization of DORs
with MOR(M) (Figures 4D and 4E). It can thus be concluded that
the MOR/DOR interaction is required for receptor cointernaliza-
tion. Most importantly, the MOR/DOR interaction was reduced
in HEK293 cells that were triple-transfected with plasmids
expressing DOR, MOR and a-CGRP1–25-MORTM1 (Figure 4B),
indicating that the MORTM1 peptide can competitively disrupt
the MOR/DOR interaction. Immunocytochemistry showed that
the coexpression of MORTM1 attenuated both the Delt I- and
DAMGO-induced MOR/DOR cointernalization (Figure 4F). Thus,
the MORTM1 peptide can be used to disrupt the MOR/DOR inter-
action, and abolish the agonist-induced cointernalization.
TAT-Directed Membrane Insertion
of the Transmembrane Domain of MOR
To evaluate the physiological relevance of receptor hetero-olig-
omerization, a method allowing the in vivo dissociation of
GPCRs is required. Because the intracellular delivery of proteins126 Neuron 69, 120–131, January 13, 2011 ª2011 Elsevier Inc.can be achieved by the fusion of proteins to the TAT peptide
(YGRKKRRQRRR) (Schwarze et al., 1999), we tested whether
this peptide could be used to insert fusion proteins into the
plasma membrane. The MORTM1-TAT protein was thus
prepared by fusion of the TAT peptide at the C terminus of the
MORTM1 peptide, and GST and Flag tags at the N terminus of
the peptide (Figure 5A). To examine the localization of the
MORTM1-TAT protein, primary DRG neurons cultured from
mice were incubated with the fusion protein and subjected to
permeabilized or non-permeabilized immunostaining with
antibodies against GST. Interestingly, we found that the
MORTM1-TAT protein was mainly located in the plasma
membrane of 91% cultured small DRG neurons (n = 123).
Some MORTM1-TAT-containing vesicular structures were
observed in the cytoplasm (Figure 5A). A lower number of
cultured large DRG neurons was also stained (43%, n = 40).
These results indicate that MORTM1-TAT can be effectively
inserted into the plasma membrane of small DRG neurons as
a result of both the penetration capacity of the TAT peptide
and the hydrophobic property of the transmembrane domain.
Figure 6. MORTM1-TAT Enhances Morphine
Analgesia
(A) The tail-immersion test at 52C showed that
morphine (2 mg/kg, s.c.)-induced analgesia was
enhanced by a 2.5 hr pretreatment with
MORTM1-TAT (i.p., three injections, 10 mg/kg/
injection, n = 10); it was not enhanced by pretreat-
ment with TAT-MORTM1 (n = 9) or MORTM3-TAT
(n = 11) at the same dosage. The time course
showed that the MORTM1-TAT-enhancing effect
of morphine lasted for at least 60 min (p < 0.001
at 15min and 30min and p < 0.01 at 60min, versus
control; n = 11 and 10 for control mice and mice
treated with MORTM1-TAT, respectively) and was
the highest 30 min after injection of the morphine.
MORTM1-TAT enhanced the morphine effect in
a dose-dependent manner (p < 0.01 at 30 min,
5 mg/kg/injection, n = 7; p > 0.05 at 30 min, 1 mg/kg/injection, n = 9). Results are presented as mean ± SEM. See also Table S3.
(B) Delt I-induced spinal analgesia was unaffected in mice treated with MORTM1-TAT (n = 10), versus control mice (n = 11). Results are presented as mean ± SEM.
See also Table S4.
(C) The tolerance to morphine was demonstrated by the loss of the analgesic response using a daily subcutaneous administration (s.c.) of 5 mg morphine/kg
during 5 days (n = 21). The daily administration of MORTM1-TAT (i.p., three injections within 2.5 hr/day, 10 mg/kg/injection) in mice (n = 11) resulted in a reduced
tolerance, while treatment with MORTM3-TAT (i.p., three injections within 2.5 hr/day, 10 mg/kg/injection, n = 10) had no effect. Analgesia was tested 30 min after
administration of morphine with the tail-flick assay. Results are presented as mean ± SEM. See also Table S5.
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the plasma membrane in the same direction as that of TM1 in
the native MOR. Nonpermeabilized immunostaining with GST
antibodies showed that the N terminus of the MORTM1 peptide
was located on the extracellular side of the plasma membrane
(Figure 5A). In contrast, when the TAT peptide was fused at the
N terminus of the MORTM1 peptide (TAT-MORTM1), the fusion
protein was inserted into the plasma membrane in a direction
opposite to that of TM1 in the native MOR, as evidenced by
the fact that the GST fused at the N terminus of the MORTM1
peptide was largely undetectable by nonpermeabilized immu-
nostaining (Figure 5A). The same patterns of membrane insertion
were observed for the MORTM3-TAT and TAT-MORTM3 proteins
in cultured small DRG neurons (Figure 5A). It can thus be
concluded that the TAT peptide serves as both a cell-penetrating
element and a guiding signal that determines the membrane
insertion direction in these fusion proteins.
Disruption of the MOR/DOR Interaction
in the Dorsal Spinal Cord
We decided to test whether MORTM1-TAT could disrupt the
MOR-DOR interaction in the dorsal horn of the spinal cord.
MORTM1-TAT was intraperitoneally infused (i.p., three injections
within 2.5 hr, 10 mg/kg/injection) in mice. A pre-embedding
immunogold-silver staining showed that MORTM1-TAT could
be transported to the lamina I–II of the mouse spinal cord
and associated with the membrane of afferent terminals (Fig-
ure 5B). A quantitative analysis showed that 68.8% ± 7.9% of
the immunogold-silver particles (n = 44) were associated with
the plasma membrane of axon terminals in the lamina II
of the mouse spinal cord. Immunoblotting further proved the
presence of MORTM1-TAT in the dorsal spinal cord after intra-
peritoneal infusion (Figure 5C). These results indicate that the
systemically applied MORTM1-TAT can be transported into the
spinal cord and inserted into the plasma membrane of afferent
terminals.The systemically applied MORTM1-TAT was found to reduce
the DOR-mediated MOR ubiquitination in the spinal cord. CoIP
experiments showed that the MOR/DOR interaction in the
mouse spinal cord was significantly reduced by applying
a 2.5 hr treatment with MORTM1-TAT (i.p., three injections,
10 mg/kg/injection) (Figure 5C). The same treatment also
reduced the Delt-induced ubiquitination of MORs in the mouse
spinal cord. However, it did not reduce DOR ubiquitination
(Figure 5D). MORs also interact with a2A-adrenergic receptors
(a2A-ARs) (Jordan et al., 2003) and neurokinin 1 receptors
(NK1-Rs) (Pfeiffer et al., 2003). It was found that MORs colocalize
with a2A-ARs in primary sensory afferents (Overland et al., 2009)
or NK1-Rs in some neurons in the spinal lamina I (Spike et al.,
2002). CoIP experiments showed that MORs interacted with
a2A-ARs and NK1-Rs in the mouse spinal cord (Figures 5C and
S3). However, neither the MOR/a2A-AR interaction nor the
MOR/NK1-R interaction was reduced by systemically applied
MORTM1-TAT (Figures 5C and S3). These results suggest that
the membrane insertion of MORTM1-TAT results in selective
disruption of the MOR/DOR interaction.
Facilitation of Morphine Analgesia by MORTM1-TAT
Finally, we examined whether a disruption of the MOR/DOR
interaction in the spinal cord would lead to a modulation of
morphine analgesia. We found that systemically applied
MORTM1-TAT protein reduced the DOR-mediated suppression
of morphine analgesia. When the MORTM1-TAT protein was
applied 2.5 hr (i.p., three injections, 10 mg/kg/injection) prior to
the morphine treatment (2 mg/kg, s.c.), the spinal analgesic
effect of morphine was facilitated with 3-fold increase at the
peak level (Figure 6A). The enhancement of the morphine effect
lasted for at least 60 min (Figure 6A). Moreover, MORTM1-TAT
protein also increased the antinociceptive effect of morphine in
a dose-dependent manner (Figure 6A; Table S3).
It was found that the MORTM1-TAT-induced effect was
specific. Indeed, neither TAT-MORTM1, which was inserted inNeuron 69, 120–131, January 13, 2011 ª2011 Elsevier Inc. 127
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(Figure 6A; Table S3). The spinal analgesia induced by Delt I
(2.5 mg, i.t.) was unaffected (n = 9) (Figure 6B; Table S4). These
results strongly suggest that DORs normally suppress MOR
activity in the spinal cord, and morphine analgesia can be
increased by a physical dissociation of MORs and DORs.
Additionally, it was found that the infused MORTM1-TAT
reduced the tolerance to morphine. The analgesic effect of
morphine was found to be reduced in mice 3 days after the
morphine treatment (2 mg/kg/day, s.c.) (Figure 6C; Table S5).
MORTM1-TAT or MORTM3-TAT was applied daily (i.p., three
injections within 2.5 hr, 10 mg/kg/injection) prior to the daily
subcutaneous administration of morphine (5 mg/kg, s.c.).
In contrast to the untreated mice, the antinociceptive effect of
morphine in MORTM1-TAT-treated mice was largely intact for
3–4 days andwasmaintained at70%of the initial effectiveness
for 9–10 days (Figure 6C; Table S5). These results suggest that
disrupting the MOR/DOR interaction in the spinal cord with the
MORTM1-TAT protein can prevent morphine tolerance.
DISCUSSION
The present study shows that the activation of DORs in MOR/
DOR complexes on the cell surface leads to a cointernalization
and codegradation of MORs and DORs. Based on the colocali-
zation of MORs and DORs in nociceptive afferent fibers, it can
be concluded that a DOR-mediated downregulation of MORs
can also be induced in the spinal dorsal horn. This process can
be attenuated by systemically applying MORTM1-TAT to disso-
ciate MORs from DORs in sensory afferents and improve
morphine-induced spinal analgesia. The physical dissociation
of MORs from DORs in the pain pathway could therefore be
exploited to enhance MOR-mediated analgesia and reduce the
associated side effects.
DOR-Mediated Postendocytotic Processing of MORs
After receptor-selective agonist stimulation, DORs are internal-
ized and often concentrated in lysosomal compartments for
degradation (Bao et al., 2003; Gaudriault et al., 1997; Trapaidze
et al., 1996; Tsao and von Zastrow, 2000), while MORs are
internalized by agonists such as DAMGO and mainly processed
in the recycling pathway for resensitization (Law et al., 2000;
Qiu et al., 2003). The present study shows that MORs and
DORs can be cointernalized by activating either DORs or
MORs with a receptor-specific agonist. However, the postendo-
cytic pathway of MORs can be shifted to lysosomal degradation
when DORs in the receptor complex are activated. This agonist-
induced effect on the MOR/DOR trafficking is determined by
distinct biochemical processes. The DOR- or MOR-selective
agonist only induces the phosphorylation of the corresponding
type of opioid receptor. Receptor cross-phosphorylation, which
occurs between MORs and somatostatin receptors or NK1-Rs
(Pfeiffer et al., 2003), was not observed between MORs and
DORs.
Interestingly, treatment with a DOR agonist elevates the
ubiquitination of both DORs and MORs, whereas the MOR
agonist DAMGO does not change the constitutive ubiquitination
of both receptors. These findings are consistent with the notion128 Neuron 69, 120–131, January 13, 2011 ª2011 Elsevier Inc.that a receptor endocytosis can be carried out in a ubiquitin-
dependent or ubiquitin-independent way (Holler and Dikic,
2004). Although ubiquitination might be unnecessary for DOR
degradation (Tanowitz and von Zastrow, 2002), the correlation
between such a modification and the MOR/DOR degradation
provides a mechanism for the DOR-mediated modulation of
the postendocytic processing of MORs.
The MOR/DOR Interaction in the Pain Pathway
In cotransfected cells, MORs and DORs form heteromers
(Daniels et al., 2005; Fan et al., 2005; Gomes et al., 2004; Jordan
and Devi, 1999). The occupancy of DORs by antagonists may
enhance MOR binding and signaling activity (Gomes et al.,
2004). Although MOR/DOR heteromers were found in a
membrane obtained from the spinal cord (Gomes et al., 2004),
reports on the coexpression of opioid receptors in DRG neurons
have been controversial. The presence of DORs andMORs in the
same neurons (Ji et al., 1995; Rau et al., 2005) and the absence
of DOR1-EGFP in MOR-containing neurons (Scherrer et al.,
2009) were both reported. However, the later finding could not
exclude that the absence of DOR1-EGFP in small neurons might
be due to transcriptional modifications during the knockin proce-
dure or to the degradation of newly synthesized DOR1-EGFP
because of its inability to adopt the conformation that is required
for trafficking in secretory pathways. The above-mentioned
in situ double-hybridization experiments have revealed the coex-
istence of DORs andMORs in a considerable population of small
DRG neurons, consistent with results obtained with other
approaches (Wang et al., 2010). These results, together with
the recent finding of opioid receptor heteromers in DRG neurons
(Gupta et al., 2010), suggest that the coexpression of MORs and
DORs in nociceptive afferent neurons is a cellular basis for their
interaction in the pain pathway.
Pharmacological and genetic data indicate that the MOR-
mediated spinal analgesia is negatively regulated by activation
of DORs and that the tolerance to morphine can be reduced
by a pharmacological blocking or genetic deletion of DORs
(Chefer and Shippenberg, 2009; Fan et al., 2005; Gallantine
and Meert, 2005; Gomes et al., 2004; Nitsche et al., 2002;
Schiller et al., 1999; Standifer et al., 1994; Xie et al., 2009; Zhu
et al., 1999). Although the MOR-mediated analgesia was unaf-
fected by the deletion of the Oprd1 exon 1 in mice (Scherrer
et al., 2009), it remains unclear whether this distinct phenotype
is due to the truncated DOR1 protein that remained in themutant
mice (Wang et al., 2010). Our finding on the improvement of
morphine-induced analgesia by disrupting the MOR/DOR inter-
action further supports the role of DORs in the regulation of
MOR-mediated analgesia.
The DOR activation-induced reduction of the number of MORs
on the cell surface could be important in the regulation of the
neuronal sensitivity to m-opioids. The MOR/DOR interaction
may be enhanced by opioid agonist stimulation and membrane
depolarization that induce the surface expression of intracellular
DORs in the pain pathway (Bao et al., 2003; Cahill et al., 2001;Ma
et al., 2006; Patwardhan et al., 2005; Walwyn et al., 2005).
Prolonged morphine treatments increase the cell surface
expression of intracellular DORs (Gendron et al., 2006; Morinville
et al., 2003) and theMOR/DORheteromerization in DRG neurons
Neuron
Functions of Opioid Receptor Interaction(Gupta et al., 2010). Although our immunostaining procedure
may not be sensitive enough to detect low levels of DORs in
the dorsal horn neurons, prolonged morphine treatments also
induce a surface expression of DORs in spinal interneurons
(Morinville et al., 2003). Therefore, chronic morphine treatments
may enhance the DOR-mediated inhibitory effects on the MOR
activity. It is also possible that surface-expressed DORs are
accessible to opioid peptides, such as ENK, that are released
from spinal interneurons (Cesselin et al., 1989) and would thus
be involved in the regulation of MOR activity in afferent terminals.
TAT Peptide Serving As a Guide for Oriented
Membrane Insertion of Proteins
It is noteworthy that the TAT peptide can serve as a guiding
signal in the MORTM1-TAT protein, enabling the insertion of the
exogenous TM1 peptide into the plasma membrane in the direc-
tion that is required for its function. This method provides an
approach to analyze the functional roles of a receptor interaction
in vivo by physically dissociating two types of GPCR in the
plasma membrane, while maintaining the function of each type
of GPCR. The identification of the heteromerization interface of
GPCRs is required for designing a molecular probe that effec-
tively disrupts the receptor interaction. The present study shows
that the insertion direction of the transmembrane domain of
a receptor can be determined by the fusion of the TAT peptide
at either the C or N terminus. This determination is based on
both the identification of the transmembrane domain specifically
mediating the receptor interaction and the membrane penetra-
tion capacity of the TAT peptide. Using such an approach to
specifically disrupt the physical interaction between receptors
and/or ion channels in the plasma membrane is not only a tool
for the functional analysis of the membrane protein interaction
in vivo but also a potential strategy for medical intervention.
Increased Opioid Analgesia by Disruption
of the MOR/DOR Interaction
The present study shows that a systemically applied MORTM1-
TAT protein disrupts the MOR/DOR interaction in the spinal
cord and improves morphine analgesia. This result is consistent
with findings on enhancedmorphine analgesia obtained by other
pharmacological or genetic approaches. The finding that
morphine analgesia is strongly enhanced by disrupting the basal
MOR/DOR interaction in the spinal cord with a membrane-in-
serted MORTM1-TAT protein suggests that DORs in the MOR/
DOR complexes can be activated by endogenous opioid-
peptides, such as ENK, that are released from the dorsal
horn neurons in response to nociceptive stimulation (Cesselin
et al., 1989). Therefore, suppression of the MOR activity by
endogenous d-opioid peptides could play a role in the homeo-
static regulation of the spinal opioid system. The MORTM1-TAT
proteins that are present in the plasma membrane could
competitively bind to DORs that are inserted into the plasma
membrane during the nociceptive stimulation and chronic treat-
ment with opioids (Bao et al., 2003; Cahill et al., 2001; Ma et al.,
2006; Patwardhan et al., 2005; Walwyn et al., 2005), thereby
attenuating the MOR/DOR interaction. Thus, MORTM1-TAT
enhances morphine analgesia and reduces the tolerance to
morphine by reducing the DOR-mediated suppressive effecton the MOR activity. This approach might benefit pain therapies
by reducing the dosage and side effects of morphine.
EXPERIMENTAL PROCEDURES
Plasmid Construction
The procedures for the construction of plasmids expressing Myc-DOR,
HA-MOR, MOR-Flag, MOR(M), a-CGRP1–25-MORTM1-GFP, GST-Flag-
MORTM1-TAT, and other TAT-fused proteins are provided in Supplemental
Information. All primers and oligonucleotides are listed in Table S6.
Cell Culture and Transfection
HEK293 cells were cultured in MEM containing 10% fetal bovine serum
(Invitrogen). The cells were transfected with 1–2 mg plasmid/35 mm dish or
2–3 mg plasmid/60 mm dish using the calcium phosphate method and were
cultured for 2–3 days.
In Situ Hybridization
Detailed procedure is provided in Supplemental Information. Briefly, the probe
for DOR1 was labeled with digoxigenin, and the MOR1 probe was labeled with
fluorescein. Sections of mouse DRGs were hybridized with two probes, and
then processed for detection of fluorescein and digoxigenin signals.
Immunostaining
HEK293 cells cotransfectedwithMyc-DORandHA-MOR expression plasmids
(see Supplemental Information) were preincubated with rabbit (Rb) anti-HA
antibody (1:500, Clontech), mouse anti-Myc antibody (1:200, Developmental
Studies Hybridoma Bank), and/or LysoTracker Red DND-99 (1:500, Molecular
Probes) for 30min at 37C.Cells were then treatedwith 1 mMSNC80, Delt I or II,
or DAMGO for 30 or 90 min. Cells were pretreated with the antagonist for
30 min before agonist incubation. Cells were fixed with 4% paraformaldehyde
and 0.2% picric acid and then immunostained. Cultured DRG neurons (Bao
et al., 2003) were treated with 0.5 nM TAT-fused protein three times within
12 hr and preincubated with Rb anti-GST antibody (1:1,000, Proteintech
Group) for 30 min at 37C for nonpermeabilized staining. Cells were fixed and
incubatedwith secondary antibodies conjugatedwith fluorescein. For permea-
bilized staining, cells were fixed and stained with anti-GST antibody.
Wild-type mice and Oprd1 exon 1-deleted mice (Jackson Lab) were fixed
with above fixative. Cryostat sections of L4–5 spinal segments were immuno-
stained with Rb antiserum against DOR13–17 (1:50,000, gift fromDr. R. Elde), or
a mixture of the DOR13–17 antiserum, guinea pig anti-MOR antibody (1:400,
Neuromics) and mouse anti-CGRP antibody (1:400, Celltech). Some sections
were processed for immunoperoxidase staining (Zhang et al., 1998b). For
quantification, three sections from each mouse were analyzed. The specificity
of the antibodies was tested by preabsorption with the corresponding immu-
nogenic peptides (106 M). The specificity of the DOR13–17 antiserum was
further examined in Myc-DOR1-expressing HEK293 cells and sections of the
spinal cord from Oprd1 exon 1-deleted mice.
Electron Microscopy
Pre-embedding immunogold-silver labeling was processed as previously
described (Zhang et al., 1998a). Briefly, mice were fixed with 4% paraformal-
dehyde and 0.05% glutaraldehyde. Vibratome sections of the spinal cord were
incubated with Rb anti-GST antibody (1:600) and labeled with the 1.4 nm gold
particle-conjugated secondary antibody (1:200, Nanoprobes). Ultrathin
sections were examined with an electron microscope.
Cell Surface Biotinylation and Immunoblotting
Cell surface biotinylation was performed before or after treatment with 1 mM
Delt I or SNC80 for 30 min as previously described (Bao et al., 2003). The
lysates were precipitated with streptavidin. For detection of the receptor phos-
phorylation, cells were treated with 1 mMDelt I, SNC80, or DAMGO for 30 min.
Cells were lysed in ice-cold RIPA buffer (50 mM Tris [pH 7.5], 150 mM NaCl,
10% glycerol, 0.1% Triton X-100, 0.5 mg/ml BSA). Samples were subjected
to SDS-PAGE, transferred to membranes, probed with the indicated anti-
bodies, and visualized with enhanced chemiluminescence. L4–5 spinalNeuron 69, 120–131, January 13, 2011 ª2011 Elsevier Inc. 129
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immunoblotting. Antibodies against Flag (1:1,000, Sigma), Myc (1:2,000),
DOR13–17 (1:5,000), DOR11–60 (1:1,000, Santa Cruz), phospho-DOR (Ser363)
(1:1,000, Neuromics), phospho-MOR (Ser375) (1:1,000, Neuromics), and actin
(1:10,000, Santa Cruz) were used. The specificity of the DOR13–17 antiserum
was examined by using spinal cord extracts from Oprd1 exon 1-deleted
mice. Intensities of immunoreactive bands of the proteins versus actin were
quantified.
Immunoprecipitation
Detailed procedure is provided in Supplemental Information. Briefly, the
suspended lysate of cells and tissues was precipitated with 0.52 mg of anti-
bodies. For detection of the receptor ubiquitination, cells or tissues were lysed
in 0.1 ml RIPA buffer with 10 mMN-ethylmaleimide and then mixed with 0.3 ml
of 8 M urea. The lysate-urea suspension was diluted to reduce the urea
concentration to 2 M and subjected to immunoprecipitation. Immunoprecipi-
tates were processed for immunoblotting. The specificity of the DOR11–60 anti-
serum was tested using spinal cord extracts fromOprd1 exon 1-deleted mice.
Preparation of GST- and TAT-Fused Proteins
GST- and TAT-fused proteins were expressed and purified. Briefly, the
proteins were expressed in Escherichia coli BL21 (DE3). The bacteria were
harvested by centrifugation, resuspended, and sonicated. The proteins were
purified with glutathione-Sepharose beads, concentrated and quantitatively
analyzed.
Drug Treatments and Behavior Tests
Experiments complied with the policy of the Society for Neuroscience (USA) on
the use of animals. Adult male mice were maintained on a 12 hr light/dark
cycle. Studies were conducted during the light phase of the cycle. The antino-
ciceptive effect was assessed using the tail-flick test. The latency to the first
sign of a rapid tail-flick was taken as the behavioral endpoint. Each mouse
was tested for baseline latency by immersing one-third of its tail in 52C water
and recording the time to response. All drugs dissolved in 5 ml of distilled water
were administered via lumbar puncture. Delt I or Delt I with NTI, SNC80, or
L-ENK was administered i.t. 30 min before the morphine treatment (1.5 mg,
i.t.). NTI (1 mg, i.t.) was administered together with morphine (1 mg, i.t.). TAT-
fused proteins (1, 5, or 10 mg/kg) were applied (i.p.) 2.5 hr, 1.5 hr, or 30 min
before themorphine treatment (2mg/kg, s.c.). Amaximum scorewas assigned
(100%) to animals not responding within 10 s to avoid tissue damage. Antino-
ciception was calculated by the following formula:%maximum possible effect
(M.P.E) = 100 3 (test latency  baseline latency)/(10  baseline latency).
Statistics
Data are presented as mean ± SEM. Statistical analysis was performed using
PRISM (GraphPad Software) with a two-tailed, paired or unpaired Student’s
t test. For behavioral tests, single-dose data were analyzed using one-way
ANOVA, followed by a two-tailed, unpaired Student’s t test for between group
comparisons. Differences were considered significant at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, six tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.neuron.2010.12.001.
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